<DOC>
	<DOC>NCT02633839</DOC>
	<brief_summary>This is an open label, parallel group study to evaluate the pharmacokinetics (PK) and safety of a single dose of CVT-301 in smoking and non-smoking adults.</brief_summary>
	<brief_title>A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults</brief_title>
	<detailed_description />
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Body mass index (BMI) 18 to 32 kg/m2; Forced expiratory volume in one second (FEV1) ≥80% of predicted for race, age, sex, and height; FEV1/FVC (forced vital capacity) ratio ≥70%; Smokers are defined as those currently smoking at least 10 cigarettes/day for at least 12 months with a positive urinary cotinine result and with no past (within 5 years) or present history of intrinsic lung disease (e.g. asthma, chronic obstructive pulmonary disease [COPD], chronic bronchitis, or other relevant conditions); Nonsmokers are defined as those who never smoked or were exposed to less than 1 pack year within at least 12 months and with a negative urinary cotinine result. Subject who is not surgically sterile or female subject who is less than 2 years postmenopausal, and who does not agree to use a highly effective birth control method during the study and up to 3 months after the last dose of investigational product; Any flulike syndrome or other respiratory infections within 2 weeks prior to the Screening Visit; History of chronic obstructive pulmonary disorder (COPD) requiring intermittent or continuous use of any oral or inhaled medication therapy within last 3 years; Renal impairment as defined by a calculated creatinine clearance of ≤ 80 mL/minute; History of syncope within the last 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Adults</keyword>
</DOC>